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ABSTRACT 1	
Background & Aims: Histamine intolerance is a disorder in the homeostasis of histamine due 2	
to a reduced intestinal degradation of this amine, mainly caused by a deficiency in the enzyme 3	
diamine oxidase (DAO). Among histamine related symptoms, headache is one of the most 4	
recorded. Current clinical strategies for the treatment of the symptomatology related to this 5	
disorder are based on the exclusion of foods with histamine or other bioactive amines and/or 6	
exogenous DAO supplementation. The aim of this study was to assess the efficacy of a food 7	
supplement consisting of DAO enzyme as a preventive treatment of migraine in patients with 8	
DAO deficiency through a randomized double-blind trial. 9	
Methods: 100 patients with confirmed episodic migraine according to current International 10	
Headache Society (IHS) criteria and DAO deficiency (levels below 80 HDU/ml) were 11	
randomized in two groups. One group received DAO enzyme supplementation and the other 12	
received placebo for one month. Clinical outcomes assessed were duration and number of 13	
attacks, perception of pain intensity and adverse effects during treatment. The use of triptans 14	
was also recorded.  15	
Results: Great variability was found in the duration of migraine attacks reported by placebo 16	
and DAO groups. A significant reduction (p=0.0217) in hours of pain was achieved in patients 17	
treated with DAO supplement, with mean durations of 6.14 (±3.06) and 4.76 (±2.68) hours 18	
before and after treatment, respectively. A smaller reduction without statistical signification 19	
was also observed for this outcome in the placebo group, from 7.53 (±4.24) to 6.68 (±4.42) 20	
hours. Only in DAO group, a decrease in the percentage of patients taking triptans was 21	
observed. The number of attacks and the scores of pain intensity showed a similar reduction 22	
in both groups. No adverse effects were registered in patients treated with DAO enzyme. 23	
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Conclusions: Migranous patients supplemented with DAO enzyme during one month 24	
significantly reduced the duration of their migraine attacks by 1.4 hours. No statistically 25	
significant reduction was found in placebo group before and after treatment. The reduction 26	
of pain hours observed in placebo group (0.9 hours) could explain the lack of significant 27	
differences between both study groups. One month of DAO supplementation has 28	
demonstrated a positive trend in the improvement of migraine but more studies with a longer 29	
treatment period are needed to better assess the efficacy of DAO supplementation. 30	
Clinical trial registration number ISRCTN10091019; www.isrctn.org. 31	
Keywords: Diamine oxidase (DAO); DAO supplementation; Histamine; Histamine intolerance; 32	
Migraine.  33	
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1. INTRODUCTION 34	
Histamine is a bioactive amine with essential physiological activities, which can also be found 35	
in some common foods in a wide range of concentrations (1,2). Histamine from diet is 36	
principally metabolized in the digestive tract by diamine oxidase (DAO), regulating its presence 37	
in the systemic circulation (3). DAO deficiency could be one of the main causes of histamine 38	
intolerance, an alteration in the homeostasis of histamine, which results in a reduced 39	
intestinal degradation, and its subsequent increase in plasma (3,4). DAO deficiency may be 40	
congenital; resulting from genetic mutations in DAO gene (chromosome 7q36) that code for 41	
an altered protein with low enzymatic activity (5-7), or acquired by certain pathologies that 42	
limit DAO secretion, especially in inflammatory or degenerative intestinal disorders (8-10), or 43	
by enzymatic blockade by some commonly used drugs (4,5). Multifaceted clinical symptoms 44	
associated with histamine intolerance include headaches, skin reactions such as urticaria and 45	
pruritus, gastrointestinal disorders as flatulence, diarrhea, nausea and abdominal pain, 46	
sneezing, rhinorrhea, arrhythmias, hypotension and muscle aches (4,11). Headache is one of 47	
the symptoms most frequently related to histamine intolerance. Reduced DAO activity has 48	
been described by several clinical studies in patients diagnosed with some pathology such as 49	
atopic eczema, chronic urticaria, chronic abdominal pain or inflammatory bowel diseases 50	
(9,10,12-15). A recent study also reported a high prevalence (87%) of DAO deficiency in a 51	
group of 137 patients diagnosed with migraine (16). 52	
Migraine is a neurological and disabling pathology with a multifactorial etiology that can 53	
negatively impact both family and work activities. Its prevalence in Spanish population has 54	
been estimated to be 12% (17). Physiopathological mechanisms supporting the onset of 55	
migraine are complex, but several pathways have been described to explain the association 56	
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between histamine and headache. In the nervous system, certain neurons synthesize 57	
histamine in the posterior-basal hypothalamic nuclei, an area recently postulated as the locus 58	
of diverse primary headaches due to increased activity detected during the prodromal phases 59	
of migraine attacks (18). Although it was first thought that histamine did not cross the blood-60	
brain barrier, it seems that it may stimulate hypothalamic activity through the 61	
circumventricular organs, which lack this barrier (18). For this reason, high plasmatic 62	
histamine levels could originate an increase of histamine in hypothalamus. Moreover, 63	
neurogenic inflammation involves the release of histamine, which, in turn, promotes the 64	
release of substance P and the gene-related peptide, both closely linked to the pain process 65	
in migraine patients (19). On the other hand, histamine could also induce a vascular headache, 66	
since its plasmatic increase would provoke a release of nitric oxide upon stimulation of H1R 67	
receptors found in intracranial arteries (4). 68	
DAO deficiency is responsible of plasmatic histamine accumulation, thus hypothetically could 69	
be one of the migraine triggers. The aim of this study is to assess the efficacy of DAO 70	
supplementation as a preventive treatment in migraine patients with DAO deficiency through 71	
a randomized double-blind trial. 72	
 73	
2. METHODS 74	
2.1. Subjects  75	
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A double-blind randomized study was carried out with 100 patients with confirmed episodic 76	
migraine diagnosis according to current International Headache Society (IHS) criteria (20) and 77	
DAO deficiency.  78	
A total of 139 participants diagnosed with migraine were recruited by the Headache Unit of 79	
the Hospital General de Catalunya (Sant Cugat del Vallès, Barcelona). After DAO activity 80	
determination, 119 of them were eligible candidates to be included in the study (migraine 81	
diagnosis and DAO deficiency). Finally, 100 patients were selected by applying additional 82	
criteria. Inclusion criteria were the age between 18 and 65 years old and 4 to 14 migraine 83	
episodes/month for a minimum of six months prior to study start. Exclusion criteria were: the 84	
onset of migraine over 50 years old, the diagnosis of other kind of headache in the same 85	
patient, pregnancy and the following of a preventive treatment for episodic migraine during 86	
three months prior to the study.  87	
DAO activity was determined from plasma samples with an enzymatic immunoassay method 88	
(D-HIT, Sciotec, Austria) after an 8-hour fasting period. Serum DAO levels below the cut-off 89	
value of 80 HDU/ml were considered as DAO deficient. 90	
2.2. Outcome measures 91	
Clinical outcomes assessed were duration and number of migraine attacks, perception of pain 92	
intensity and adverse effects during treatment. The duration of migraine attacks was 93	
measured by the number of hours of pain. Pain intensity was assessed by the Numeric Pain 94	
Rating Scale (NPRS), a 10-point grading scale where 0 represents absence of pain and 10 is the 95	
worst possible pain.  96	
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Other complementary information has been also recorded, such as adverse effects during 97	
treatment and the use of specific analgesic drugs, specifically the intake of triptans during 98	
migraine attacks. Data about the number of triptans in each migraine attack was recorded per 99	
patient, classifying their intake as low (less than 5 capsules/month), moderate (between 6 and 100	
10 capsules/month) and high (more than 10 capsules/month).  101	
2.2. Study protocol  102	
Figure 1 provides details of the study design. In baseline consultation (C0) patients received a 103	
first diary to record data related to the outcome measures during one month prior to the 104	
study. After one month, all patients were scheduled for the first consultation (C1) and 105	
submitted the completed first diary. Patients were then randomized in two groups (DAO and 106	
placebo) and received a second diary to record the information requested during the month 107	
of treatment, which they submitted in a second consultation (C2). 108	
Randomization in two groups was double-blind using the RANUNI procedure (SAS, v. 6.12, SAS 109	
Institute, Cary, NC, USA). One group received DAO enzyme supplementation (n=50) and the 110	
other placebo (n=50). Stratification considering age and sex was applied to assure similarity in 111	
baseline characteristics of both groups. The treatment consisted in the oral administration of 112	
2 capsules of DAO supplement or placebo 20 minutes before breakfast, lunch and dinner. Each 113	
capsule contained 4.2 mg of porcine kidney protein extract with 7% of DAO with an enzymatic 114	
activity of 10,000 HDU/ml. The content of the capsules was microencapsulated with a 115	
gastroresistent shellac coating. Placebo consisted of microcrystalline cellulose and gelatin 116	
capsules with the same form, size and color than DAO ones and was provided by the same 117	
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manufacturer. Treatment compliance was verified by counting the remaining capsules for 118	
each patient. 119	
Table 1 shows the characteristics (sex, age and DAO activity) of all patients included in both 120	
study groups. 121	
The Ethics Committee of the Hospital General de Catalunya approved the study and all 122	
participants signed an informed consent form. 123	
2.4. Statistical analysis 124	
The size of the sample was calculated assuming a 5% type 1 error rate and a desired statistical 125	
power of 80%. Taking into account a minimal detectable mean difference of 1.25 126	
attacks/month with a SD of 2, a total of 82 subjects would be needed. Based on an expected 127	
15% dropout rate, a total of 100 patients (50 per group) were included to assure that at least 128	
82 subjects would complete the full study. 129	
T-test was used to evaluate differences within groups before (C1) and after (C2) treatment 130	
and between groups (placebo and DAO) in migraine attack duration (hours), number of 131	
attacks, and pain scales. Chi-squared test was used to determine significant differences in 132	
patients taking triptans. Probability values of P<0.05 were accepted as significant. Statistical 133	
analysis was performed using a SPSS for Windows, version 22 (Chicago, IL). 134	
3. RESULTS  135	
No significant differences in treatment compliance were observed between both groups 136	
(p=0.543), with a mean (SD) of remaining capsules of 17 (20.6) and 19.9 (24.7) in placebo and 137	
DAO group, respectively. 138	
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Great variability was found in the duration of migraine attacks reported by placebo and DAO 139	
groups, with some extremely high values recorded (Figure 2). Values exceeding that obtained 140	
by the formula P75 + 3·IQR (IQR: interquartile range; P75-P25) were statistically considered as 141	
extreme outlier values, and the corresponding patients were excluded, resulting in a final 142	
sample of 82 subjects, 43 in the placebo and 39 in the DAO group. 143	
Table 2 shows the duration of migraine attacks, as the mean of pain hours for each patient 144	
(total number of pain hours/number of attacks) before and after treatment. Before treatment, 145	
mean (SD) values were 7.5 hours (4.2) and 6.1 hours (3.1) for placebo and DAO group, 146	
respectively. A statistically significant reduction in the duration of pain was obtained in DAO 147	
group after one month of treatment (p=0.0217). Although to a smaller extent, a reduction in 148	
this outcome was also observed in placebo group, but without statistical signification. 149	
Regarding the difference between groups, patients treated with DAO supplement reached a 150	
higher reduction of migraine attack duration (1.4 hours) than in placebo group (0.9 hours), 151	
although with a lack of statistical signification. When considering the number of attacks, 152	
significant reduction was found both in DAO group (2.67 attacks, p=0.0004) and in placebo 153	
group (2.16 attacks, p=0.0059). Similar reductions in the frequency of migraine attacks were 154	
achieved in both study groups. Regarding pain intensity, similar scores were found before and 155	
after the treatment in both groups (Table 2).  156	
No adverse effects were registered in patients with DAO supplementation. Only one patient 157	
of the placebo group described gastrointestinal troubles and subsequently abandoned the 158	
study.  159	
Figure 3 shows the percentage of patients who used triptans before and after the treatment 160	
with placebo or DAO. A reduction of patients taking triptans was observed in DAO group 161	
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whereas in placebo group there was an increase in patients with triptans intake. Figure 4 162	
illustrates the intake of triptans before and after one month of treatment with placebo or DAO 163	
for each of the patients that reported consumption. In fact, among individuals treated with 164	
DAO, 44% of them reduced triptans intake (5 reported a total withdrawal), 30% remained 165	
unchanged and 26% increased the intake of these drugs. On the contrary, an increase in 166	
triptans intake in the placebo group was recorded in 57% of the individuals. However, in 167	
neither case the association was statistically significant. 168	
 169	
4. DISCUSSION  170	
To our knowledge, this is the first double-blind randomized trial to assess the effect of DAO 171	
supplementation in migraine patients. Currently the main measure to prevent or mitigate the 172	
symptomatology related to histamine intolerance by DAO deficiency is the dietary 173	
management avoiding foods with high contents of histamine or other bioactive amines also 174	
metabolized by DAO, such as putrescine and cadaverine, as well as foods described as 175	
histamine-releasing (4,5,21). Several intervention studies have demonstrated the 176	
effectiveness of histamine restrictive diets, some of them specifically focused on headache, 177	
with positive results in most of the patients involved in each study (12,13,22,23). However, 178	
the wide and variable distribution of histamine in foods together with other additional 179	
restrictions (histamine-releasing foods and presence of other bioactives amines) makes 180	
difficult the diet adherence and increases the risk of nutritional imbalances. The use of DAO 181	
supplementation could be an alternative to a histamine-free diet or be useful to make easier 182	
its compliance. 183	
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In our double-blind randomized clinical study, DAO enzyme supplementation consisted in 184	
porcine kidney extract microencapsulated with a shellac gastroresistant coating that 185	
guaranteed its resistance in the pH of the stomach and subsequently its hydrolysis by pepsin. 186	
Intestinal conditions allow the release of the unaltered enzyme that will potentially resist the 187	
proteolytic attack of trypsin and chymotrypsin. In fact, Federico et al. (24) reported a high in 188	
vitro stability of DAO of plant origin in the presence of trypsin, with 100% of the enzymatic 189	
activity during the first 45 minutes.  190	
The administration of the DAO supplement was able to significantly reduce the mean duration 191	
of migraine attacks by 1.4 hours (from an initial mean value of 6.1 hours). The duration of 192	
migraine attacks has been used as an efficacious measure to assess the clinical and quality of 193	
life impact of the treatment (25-27). On the other hand, the effect of this supplementation in 194	
the migraine frequency could not be established because both study groups showed a 195	
significant reduction greater than 2 monthly attacks. Moreover, the lack of significance 196	
observed between groups could be explained by the limited duration of one month of 197	
treatment. A longer intervention period might confirm the trend observed in the current study 198	
about the effects of DAO supplementation on migraine improvement.  199	
Regarding pain intensity, no differences were found based on the NPRS score reported by the 200	
subjects from both groups. The usefulness of this scale has been questioned in patients with 201	
long-term pain because they tend to score between 4 and 6 (golden section) (28). Likewise, 202	
the use of triptans (allowed in this study), could cover up the real perception of pain.  203	
Patients with DAO deficiency could be stratified as reduced DAO activity level (40-80 HDU/ml) 204	
and markedly reduced DAO activity level (<40 HDU/ml). In this study, only few individuals 205	
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showed a markedly reduced DAO activity, with 7 and 4 patients in the placebo and DAO group, 206	
respectively. The reduced number of subjects with markedly reduced DAO activity, which did 207	
not allow the stratification of these patients, together with the fact that all subjects received 208	
the same dose of treatment, could diminish the strength of the current study.  Markedly 209	
reduced DAO activity patients could require a higher dose to reach the improvement of 210	
symptomatology. 211	
A trend to diminish the triptans intake was observed in DAO group, with some patients that 212	
abandoned the use of triptans. A reduction of the number of patients with low and moderate 213	
intake of these drugs was also observed. The reduction in triptans intake could indicate a 214	
decrease in the intensity of pain during migraine crisis. This trend was not observed in the 215	
placebo group where the intake of triptans increased in comparison with the baseline. 216	
There are few studies about the efficacy of DAO supplementation in the improvement of 217	
headache and other symptoms associated with histamine intolerance (29,30), and all of them 218	
with a lower number of patients involved. A randomized double-blind crossover provocation 219	
study (29), using histamine containing and histamine-free tea in combination with DAO 220	
capsules or placebo in 39 patients with histamine intolerance revealed that two capsules of 221	
DAO supplementation reduced the appearance of headache, skin reactions, and respiratory 222	
and gastrointestinal disorders in comparison with placebo. Recently, Manzotti et al. (30) also 223	
observed that DAO supplementation for a period of at least two weeks was associated with a 224	
reduction of one or more of the reported symptoms in 13 out of 14 patients with histamine 225	
intolerance. When DAO supplementation was associated with low-histamine diet a higher 226	
reduction of symptoms was reported in comparison to the diet alone. However, in this study 227	
no placebo group was considered.  228	
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In the current trial the efficacy of DAO supplementation was assessed after only one month 229	
of treatment, so probably, a longer treatment period could lead to a great improvement. 230	
Moreover, no complementary dietary intervention was considered, and then it is possible that 231	
DAO supplementation together with histamine free-diet could enhance the results of the 232	
treatment. Likewise, in further studies it would be of interest to segregate patients in different 233	
grades of DAO deficiency. Therefore, more randomized placebo-controlled studies, preferably 234	
with a cross-over design, are needed to assess the benefits of DAO supplementation for a 235	
longer treatment period, and the combined effect of DAO supplement together with 236	
histamine free diet, which would make diets less restrictive and improve patients quality of 237	
life. 238	
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Table 1. Characteristics (sex, age and DAO activity levels) of all patients included in both 
placebo and DAO groups. 
 
SD: 
standard deviation; min: minimum; max: maximum; HDU : histamine degrading units. 
  253	
VARIABLE  PLACEBO N=43 
DAO 
N=39 
TOTAL 
N=82 
Sex 
(number of 
patients) 
Female 36 32  68 
Male 7  7 14  
Age  
(years old) 
Mean (SD) 
min-max 
43.6 (11.0) 
23.8-64.9 
40.8  (10.9) 
18.4-61.2 
42.3 (11.0) 
18.4-64.9 
DAO activity 
(HDU/ml) 
Mean (SD) 
min-max 
54.8 (11.3) 
18.6-79.6 
53.3 (11.2) 
22.6-79.0 
54.1 (12.9) 
18.6-79.6 
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Table 2.  Duration, number and pain intensity of migraine attacks in placebo and DAO groups 
before (C1) and after one month of treatment (C2). 
																
 
 
 
 
 
 
SD: standard deviation; min: minimum; max: maximum; NPRS: Numeric Pain Rating Scale. 
a p-value for the statistical difference between placebo and DAO groups; b: p-value for the statistical differences between before (C1) and 
after (C2) treatment.  
   PLACEBO N = 43 
DAO 
N = 39 P
 a 
DURATION OF 
ATTACKS 
(HOURS) 
Before treatment (C1) Mean (SD) min - max 
7.53 (4.24) 
0 - 21 
6.14 (3.06) 
1.8 - 15 
 
After treatment (C2) Mean (SD) min - max 
6.68 (4.42) 
0 - 16.5 
4.76 (2.68) 
0 - 11   
 Pb 0.3034 0.0217  
 
C2-C1 Mean (SD) min - max 
-0.85 (5.35) 
-15.2 – 10.5 
-1.38 (3.60) 
-15.0 – 6.6 0.6040 
NUMBER OF 
ATTACKS/MONT
H 
Before treatment (C1) Mean (SD) min - max 
9.26 (5.21) 
(0 - 20) 
10.18 (4.44) 
(1 - 20) 
 
After treatment (C2) Mean (SD) min - max 
7.09 (4.97) 
0 - 20 
7.51 (4.97) 
0 - 19 
 
 Pb 0.0059 0.0004  
 
C2-C1 Mean (SD) min - max 
-2.16 (4.88) 
-15.0 – 8.0 
-2.67 (4.26) 
-15.0 – 5.0 0.6172 
PAIN INTENSITY 
(NPRS SCORE) 
Before treatment (C1) Mean (SD) min - max 
5.62 (1.57) 
0 - 9 
5.27 (1.43) 
1.4 - 7.9 
 
After treatment (C2) Mean (SD) min - max 
4.88 (2.31) 
0 - 8.5 
5.07 (2.02) 
0 - 8.6 
 
 Pb 0.0885 0.5117  
 
C2-C1 Mean (SD) min - max 
-0.71 (2.67) 
-7.8 – 7.8 
-0.21 (1.98) 
-7.0 – 2. 0 0.3424 
22		
		
Figure legends 
Figure 1. Schematic representation of the study design.  
Figure 2. Box plot for the duration of migraine attacks (in hours of pain) in placebo and DAO 
groups one month before (C1) and after one month of treatment (C2). The bottom and top of 
the box (interquartile range) are the percentile 25 and the percentile 75, respectively. Central 
line represents the median. Lines extending vertically from the boxes (whiskers) indicate 
variability outside the interquartile range. Outliers are plotted as circles and extreme outliers 
as asterisks.  
Figure 3. Percentage of patients who used triptans before (C1) and after one month of 
treatment (C2) with placebo or DAO.  The triptans intake classification was: no intake, low (1-
5 capsules/month), moderate (between 6-10 capsules/month) and high (more than 10 
capsules/month).  
Figure 4. Number of capsules of triptans required before (C1) and after (C2) one month of 
treatment with placebo (A) or DAO supplementation (B) for each of the patients that reported 
consumption. Red line means an increase, green line means a decrease and black line means 
no change in the triptan intake after one month of treatment. 
		
	
STUDY PROTOCOL 
 
- Baseline consultation: a first diary was given to each patient to record data 
related to outcome measures during the month prior to treatment start. 
- Consultation 1 (C1):  
• The completed first diary was submitted and a second diary was given to record 
all information related to outcome measures during the month of treatment.  
• Patients were randomized in two groups: DAO (n=50) and placebo (n=50). 
- Consultation 2 (C2):  
• The completed second diary was submitted and treatment compliance was 
checked by counting the remaining capsules.  
• One patient from the placebo group abandoned the study. 
DATA ANALYSIS 
 
-  Patients with migraine attack durations statistically considered as extreme outliers 
were excluded for data analysis, resulting in a total of 82 subjects. 
Placebo (n=43) DAO (n=39) 
 
RECRUITMENT OF PARTICIPANTS 
 
-  From a pool of 139 patients diagnosed with migraine at the Headache Unit of the 
Hospital General de Catalunya (Sant Cugat del Vallès, Spain), 119 with DAO 
deficiency were eligible candidates to be enrolled in the study. By applying 
additional selection criteria, 100 subjects were finally included. 
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